Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
Jung Eun Park,Vy H. Nguyen,Pei‐Chien Tsai,Hidenori Toyoda,Jennifer Leong,Jennifer E. Guy,Ming‐Lun Yeh,Chung‐Feng Huang,Satoshi Yasuda,Hiroshi Abe,Yao‐Chun Hsu,Cheng‐Hao Tseng,Joanne Liu,Yao‐Li Chen,Ping‐Yi Lin,Dae Won Jun,Yoko Yoshimaru,Eiichi Ogawa,Masatoshi Ishigami,Masaru Enomoto,Akihiro Tamori,Haruki Uojima,Xiao Zhong Wang,Qiang Xu,Hirokazu Takahashi,Yuichiro Eguchi,Kaori Inoue,Daniel Q. Huang,Wen Jing Zhao,Wan‐Long Chuang,Chia‐Yen Dai,Jee‐Fu Huang,Scott Barnett,Mayumi Maeda,Ramsey Cheung,Charles Landis,Yasuhito Tanaka,Lewis R. Roberts,Myron E. Schwartz,Takashi Kumada,Ming‐Lung Yu,Mindie H. Nguyen
DOI: https://doi.org/10.1111/apt.17863
IF: 9.524
2024-01-05
Alimentary Pharmacology & Therapeutics
Abstract:Summary Background Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival. Aim To evaluate the impact of HCV treatment on such disparities. Methods In a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia. Results The mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%–15%, 20% vs. 10%–17% and 10% vs. 5%–7%, respectively; all p
pharmacology & pharmacy,gastroenterology & hepatology